The positive inotropic effect of angiotensin II - Role of endothelin-1 and reactive oxygen species

被引:61
作者
Cingolani, HE [1 ]
Villa-Abrille, MC
Cornelli, M
Nolly, A
Ennis, IL
Garciarena, C
Suburo, AM
Torbidoni, V
Correa, MV
de Hurtado, MCC
Aiello, EA
机构
[1] Natl Univ La Plata, Fac Ciencias Med, Ctr Invest Cardiovasc, RA-1900 La Plata, Argentina
[2] Univ Austral, Fac Ciencias Biomed, Buenos Aires, DF, Argentina
关键词
membranes; ion channels; oxidative stress; receptors; angiotensin;
D O I
10.1161/01.HYP.0000208302.62399.68
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Many effects believed to be because of angiotensin II ( Ang II) are attributable to the action of endothelin ( ET)-1, which is released/produced by Ang II. We investigated whether Ang II elicits its positive inotropic effect ( PIE) by the action of endogenous ET-1, in addition to the role played by reactive oxygen species ( ROS) in this mechanism. Cat cardiomyocytes were used for: ( 1) sarcomere shortening measurements; ( 2) ROS measurements by epifluorescence; ( 3) immunohistochemical staining for preproET-1, BigET-1, and ET-1; and ( 4) measurement of preproET- 1 mRNA by RT-PCR. Cells were exposed to 1 nmol/L Ang II for 15 minutes. This low concentration of Ang II increases sarcomere shortening by 29.2 +/- 3.7% ( P < 0.05). This PIE was abrogated by Na+/H+ exchanger or Na+/Ca2+ exchanger reverse mode inhibition. The production of ROS increased in response to Ang II treatment ( Delta ROS respect to control: 68 +/- 15 fluorescence units; P < 0.05). The Ang II-induced PIE and ROS production were blocked by the Ang II type 1 receptor blocker losartan, the nonselective ET-1 receptor blocker TAK044, the selective ETA receptor blocker BQ-123, or the ROS scavenger N-(2-mercapto-propionyl) glycine. Exogenous ET-1 ( 0.4 nmol/L) induced a similar PIE and increase in ROS production to those caused by Ang II. Immunostaining for preproET- 1, BigET-1, and ET-1 was positive in cardiomyocytes. The preproET- 1 mRNA abundance increased from 100 +/- 4.6% in control to 241.9 +/- 39.9% in Ang II-treated cells ( P < 0.05). We conclude that the PIE after exposure to 1 nmol/L Ang II is due to endogenous ET-1 acting through the ETA receptor and triggering ROS production, Na+/H+ exchanger stimulation, and Na+/Ca2+ exchanger reverse mode activation.
引用
收藏
页码:727 / 734
页数:8
相关论文
共 37 条
[31]   Nitric oxide donors induce late preconditioning against myocardial stunning and infarction in conscious rabbits via an antioxidant-sensitive mechanism [J].
Takano, H ;
Tang, XL ;
Qiu, YM ;
Guo, YR ;
French, BA ;
Bolli, R .
CIRCULATION RESEARCH, 1998, 83 (01) :73-84
[32]   Effects of N-(2-mercaptopropionyl)-glycine on mitochondrial function in ischemic-reperfused heart [J].
Tanonaka, K ;
Iwai, T ;
Motegi, K ;
Takeo, S .
CARDIOVASCULAR RESEARCH, 2003, 57 (02) :416-425
[33]   Endothelin-1 and endothelin receptors in light-induced retinal degeneration [J].
Torbidoni, V ;
Iribarne, M ;
Ogawa, L ;
Prasanna, G ;
Suburo, AM .
EXPERIMENTAL EYE RESEARCH, 2005, 81 (03) :265-275
[34]   Angiotensin II and endothelin-1 regulate MAP kinases through different redox-dependent mechanisms in human vascular smooth muscle cells [J].
Touyz, RM ;
Yao, GY ;
Viel, E ;
Amiri, F ;
Schiffrin, EL .
JOURNAL OF HYPERTENSION, 2004, 22 (06) :1141-1149
[35]   A novel antagonist, No 7943, of the Na+/Ca2+ exchange current in guinea-pig cardiac ventricular cells [J].
Watano, T ;
Kimura, J ;
Morita, T ;
Nakanishi, H .
BRITISH JOURNAL OF PHARMACOLOGY, 1996, 119 (03) :555-563
[36]   Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of Gαq/Gα11 in cardiomyocytes [J].
Wettschureck, N ;
Rütten, H ;
Zywietz, A ;
Gehring, D ;
Wilkie, TM ;
Chen, J ;
Chien, KR ;
Offermanns, S .
NATURE MEDICINE, 2001, 7 (11) :1236-1240
[37]   Obligatory role for endogenous endothelin in mediating the hypertrophic effects of phenylephrine and angiotensin II in neonatal rat ventricular myocytes: Evidence for two distinct mechanisms for endothelin regulation [J].
Xia, Y ;
Karmazyn, M .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 310 (01) :43-51